Fig. 1.

Possible flow-through – proteomic strategies – which may be useful for ALL-relapse research. The proteins must be purified from body-human fluids, subsequently high abundant proteins must be depleted as they can artefact the biomarkers-identification of ALL-relapses. The resulting purified proteins can be loaded into SIMAC chromatography to purify phosphorylated proteins. Finally, the peptides can be labelled via iTRAQ to quantify the level expression of phosphorylated proteins for a given clinical sample. The resulting potentially identified biomarkers by mass spectrometry, can be validated via ELISA and SRM/MRM. In addition, just by using iTRAQ plus mass spectrometry tools, the reference map of the proteome (ALL paediatric relapses) can be achieved studying the differential expressed proteins. Thus, new therapy targets can be discovered to improve current therapies for paediatric ALL relapses.